Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04135794

Acronym

MRL1

Enrollment

377

Registered

2019-10-23

Start date

2019-12-09

Completion date

2027-11-30

Last updated

2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

MRL

Brief summary

This study is being done to help further understand how MR-guided adaptive RT in conjunction with the Integrated Magnetic Resonance Linear Accelerator (MRL) can improve patient outcomes. This study will include participants who will be receiving radiotherapy using the MRL machine to target their cancer more precisely. Participants will be asked to have a few extra MR scans taken during their RT planning and to complete a few quality of life questionnaires.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients 18 years or older with a diagnosis of cancer, regardless of clinical site or stage * Planned to receive a course of MR-guided adaptive RT using the MRL * Ability to provide informed consent

Exclusion criteria

* Patients under 18 years old

Design outcomes

Primary

Measure	Time frame	Description
Disease-free and overall survival rates	Up to 5 years post-radiotherapy	Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.
Local, regional and distant tumor control rates	Up to 5 years post-radiotherapy	Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.
Complication rates measured using the Common Toxicity Criteria for Adverse Events	Within 3 months of completing treatment	Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.

Secondary

Measure	Time frame	Description
Patient experience and anxiety related to MR imaging and adaptive RT with the MR	Immediately after first MRL treatment visit	Evaluate the patient experience during adaptive RT with the MRL using the Magnetic Resonance Imaging-Anxiety Questionnaire (MRI-AQ) which measures patient anxiety and tolerability of MR-related procedures

Countries

Canada

Outcome results